Drug Approval | June 13, 2024
Torrent Pharmaceuticals gets Form 483 with 5 observations for Indrad facility
There was no observation related to data integrity reported
There was no observation related to data integrity reported
Vonoprozan is a novel potassium-competitive acid blocker used for the treatment of acid related disorders
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Subscribe To Our Newsletter & Stay Updated
